Diabetes in tomorrow's world: Dark clouds do have silver linings

Diabetes, Obesity and Metabolism

Volumn 4, Issue 6, 2002, Pages 351-355

  Shepherd, James ^a,b  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Dyslipidaemia; Fibrates; Insulin resistance; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DYSLIPIDEMIA; GENETIC PREDISPOSITION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; QUALITY OF LIFE; REVIEW; RISK FACTOR; STROKE;

EID: 0036845642     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2002.00193.x     Document Type: Review

References (21)

1. Wingard DC, Barrett-Connor E. Heart disease and diabetes. In Diabetes in America. NIH Publication No. 95-1468, 1995: 429-448.
2. UK Prospective Diabetes Study. Study design, progress and performance. Diabetologia 1991; 34: 877-890.
3. Harris MI, Flegal KM, Cowie CC et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in US adults. The Third NHANE Survey 1988-94. Diabetes Care 1998; 21: 518-524.
4. Zimmet PZ, Alberti KGMM. The changing face of macrovascular disease in NIDDM. An epidemic in progress. Lancet 1997; 350: 1-4.
5. Zimmet PZ, McCarty D. The NIDDM epidemic. global estimates and projection: a look into the crystal ball. Int Diabetes Federation Bull 1995; 40: 8-16.
6. Chockalingam A. Cardiovascular diseases: India. Let's not make the same mistakes again. Lancet Perspectives 2000; 356: S9.
7. Scottish Intercollegiate Guidelines Network Publication 19. Management of diabetic cardiovascular disease. ISBN 1 899893,1997.
8. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. New Engl J Med 2000; 342: 145-153.
9. Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New Engl J Med 1999; 341: 410-418.
10. Pyorala K, Pedersen TR, Kjekshus J et al. (for the Scandinavian Simvastatin Survival Study Group). Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614-622.
11. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996; 335: 1001-1009.
12. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New Engl J Med 1998; 339: 1349-1357.
13. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet, 1997; 348: 1079-1082.
14. Rosenson RS, Tangney CC. Anti-atherothrombotic properties of statins. JAMA 1998; 279: 1643-1650.
15. Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.
16. Shepherd J, Cobbe SM, Ford I, et al.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995; 333: 1301-1307.
17. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
18. Haffner SM, Stern MP, Hazuda HP et al. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898.
19. Sheu WHH, Shieh SM, Shen DDC et al. Effect of pravastatin treatment on glucose, insulin and lipoprotein metabolism in patients with hypercholesterolemia. Am Heart J 1994; 127: 331-336.
20. Baba T, Kodama T, Yajima Y et al. Effects of pravastatin on glucose tolerance in patients with essential hypertension. Diabetes Care 1993; 16: 402-404.
21. Shepherd J, Blauw GJ, Murphy MB et al. (On behalf of The PROSPER Study Group). The Design of a Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Am J Cardiol 1999; 84: 1192-1197.